The University of Southampton
University of Southampton Institutional Repository

Targeted genetic sequencing analysis of 223 cases of pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy shows survival related to GNAS and KRAS status

Targeted genetic sequencing analysis of 223 cases of pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy shows survival related to GNAS and KRAS status
Targeted genetic sequencing analysis of 223 cases of pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy shows survival related to GNAS and KRAS status

Background and aim: pseudomyxoma peritonei (PMP) is an unusual condition with unique behaviour caused by a mucinous neoplasm, usually arising from the appendix. The aim of this study was to evaluate the prevalence of genomic alterations in clinical specimens of PMP using a targeted assay and correlate the findings with clinical, pathological and outcome data. Sequencing data from 223 patients were analysed. 

Results: the median follow-up interval was 48 months. The primary neoplasm was appendiceal in 216 patients, ovarian in 4, urachal in 2 and renal in one. We confirmed common mutations in GNAS and KRAS (42% each) with significant co-occurrence of variants in these genes. TP53 mutations were found in 8%. Other mutations were rare but included novel mutations in BAP1 and ERBB4. Of 17 patients with acellular peritoneal mucin, 6 (35%) were positive for DNA mutations. The non-appendiceal cases generally showed a similar mutational landscape to the appendiceal lesions with GNAS and KRAS commonly mutated, although one urachal lesion showed multi-hit TP53 mutation without variants in either GNAS or KRAS. Survival was significantly associated with the grade of the primary neoplasm, the grade of the peritoneal disease, the completeness of cytoreduction score and with mutation in either GNAS, KRAS or both. The hazard ratio (HR) associated with mutation in GNAS and/or KRAS was 1.87 (p = 0.004). 

Conclusions: survival outcome was more closely associated with the grade of the peritoneal disease than with the grade of the primary neoplasm. Our findings support the developing concept that mutational analysis may provide prognostic information in patients with PMP.

2045-7634
Gibson, Jane
855033a6-38f3-4853-8f60-d7d4561226ae
Pengelly, Reuben J.
af97c0c1-b568-415c-9f59-1823b65be76d
Mirandari, Amatta
b8640936-4b35-47c5-b6f1-f4d81ab6e2f6
Boukas, Konstantinos
4cbff114-7077-45ad-95e7-2c6a03761380
Stanford, Sophia
ea11cec4-d952-4e42-b44c-70e02eb3ec66
Cecil, Thomas Desmond
d750e786-b2a0-469b-9923-95badf4730d8
Mohamed, Faheez
11e760f5-fd56-4f32-9264-22a2e710b365
Dayal, Sanjeev Paul
b22b44bc-1c90-405c-91d8-effee2546991
Tzivanakis, Alexios
3b9dbb38-ed0e-4614-92c9-b1706bea11fc
Moran, Brendan John
3465969e-87a1-4ddd-ad74-b0d1ef160f41
Mirnezami, Alex
b3c7aee7-46a4-404c-bfe3-f72388e0bc94
Carr, Norman John
810e44dc-90d5-496c-85b6-6b2fa1c07dd7
Ennis, Sarah
7b57f188-9d91-4beb-b217-09856146f1e9
Gibson, Jane
855033a6-38f3-4853-8f60-d7d4561226ae
Pengelly, Reuben J.
af97c0c1-b568-415c-9f59-1823b65be76d
Mirandari, Amatta
b8640936-4b35-47c5-b6f1-f4d81ab6e2f6
Boukas, Konstantinos
4cbff114-7077-45ad-95e7-2c6a03761380
Stanford, Sophia
ea11cec4-d952-4e42-b44c-70e02eb3ec66
Cecil, Thomas Desmond
d750e786-b2a0-469b-9923-95badf4730d8
Mohamed, Faheez
11e760f5-fd56-4f32-9264-22a2e710b365
Dayal, Sanjeev Paul
b22b44bc-1c90-405c-91d8-effee2546991
Tzivanakis, Alexios
3b9dbb38-ed0e-4614-92c9-b1706bea11fc
Moran, Brendan John
3465969e-87a1-4ddd-ad74-b0d1ef160f41
Mirnezami, Alex
b3c7aee7-46a4-404c-bfe3-f72388e0bc94
Carr, Norman John
810e44dc-90d5-496c-85b6-6b2fa1c07dd7
Ennis, Sarah
7b57f188-9d91-4beb-b217-09856146f1e9

Gibson, Jane, Pengelly, Reuben J., Mirandari, Amatta, Boukas, Konstantinos, Stanford, Sophia, Cecil, Thomas Desmond, Mohamed, Faheez, Dayal, Sanjeev Paul, Tzivanakis, Alexios, Moran, Brendan John, Mirnezami, Alex, Carr, Norman John and Ennis, Sarah (2024) Targeted genetic sequencing analysis of 223 cases of pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy shows survival related to GNAS and KRAS status. Cancer Medicine, 13 (20), [e70340]. (doi:10.1002/cam4.70340).

Record type: Article

Abstract

Background and aim: pseudomyxoma peritonei (PMP) is an unusual condition with unique behaviour caused by a mucinous neoplasm, usually arising from the appendix. The aim of this study was to evaluate the prevalence of genomic alterations in clinical specimens of PMP using a targeted assay and correlate the findings with clinical, pathological and outcome data. Sequencing data from 223 patients were analysed. 

Results: the median follow-up interval was 48 months. The primary neoplasm was appendiceal in 216 patients, ovarian in 4, urachal in 2 and renal in one. We confirmed common mutations in GNAS and KRAS (42% each) with significant co-occurrence of variants in these genes. TP53 mutations were found in 8%. Other mutations were rare but included novel mutations in BAP1 and ERBB4. Of 17 patients with acellular peritoneal mucin, 6 (35%) were positive for DNA mutations. The non-appendiceal cases generally showed a similar mutational landscape to the appendiceal lesions with GNAS and KRAS commonly mutated, although one urachal lesion showed multi-hit TP53 mutation without variants in either GNAS or KRAS. Survival was significantly associated with the grade of the primary neoplasm, the grade of the peritoneal disease, the completeness of cytoreduction score and with mutation in either GNAS, KRAS or both. The hazard ratio (HR) associated with mutation in GNAS and/or KRAS was 1.87 (p = 0.004). 

Conclusions: survival outcome was more closely associated with the grade of the peritoneal disease than with the grade of the primary neoplasm. Our findings support the developing concept that mutational analysis may provide prognostic information in patients with PMP.

Text
Targeted PMP paper v4 Revised -with tablesfigures - Accepted Manuscript
Available under License Creative Commons Attribution.
Download (2MB)
Text
Cancer Medicine - 2024 - Gibson - Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by - Version of Record
Available under License Creative Commons Attribution.
Download (3MB)

More information

Accepted/In Press date: 3 October 2024
e-pub ahead of print date: 22 October 2024
Published date: 22 October 2024

Identifiers

Local EPrints ID: 495733
URI: http://eprints.soton.ac.uk/id/eprint/495733
ISSN: 2045-7634
PURE UUID: cc29662c-bfda-4856-8770-666014d20f7c
ORCID for Jane Gibson: ORCID iD orcid.org/0000-0002-0973-8285
ORCID for Reuben J. Pengelly: ORCID iD orcid.org/0000-0001-7022-645X
ORCID for Sarah Ennis: ORCID iD orcid.org/0000-0003-2648-0869

Catalogue record

Date deposited: 21 Nov 2024 17:34
Last modified: 23 Nov 2024 02:47

Export record

Altmetrics

Contributors

Author: Jane Gibson ORCID iD
Author: Amatta Mirandari
Author: Konstantinos Boukas
Author: Sophia Stanford
Author: Thomas Desmond Cecil
Author: Faheez Mohamed
Author: Sanjeev Paul Dayal
Author: Alexios Tzivanakis
Author: Brendan John Moran
Author: Alex Mirnezami
Author: Norman John Carr
Author: Sarah Ennis ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×